{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:01:32Z","timestamp":1788850892092,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS\u2013CoV-2), is still a global public health problem for humans. It has caused more than 10,000,000 infections and more than 500,000 deaths in the world so far. Many scientists have tried their best to discover safe and effective drugs for the treatment of this disease; however, there are still no approved standard therapeutics or effective antiviral drugs on the market. Many new drugs are being developed, and several traditional drugs that were originally indicated or proposed for other diseases are likely to be effective in treating COVID-19, but their safety and efficacy are controversial, under study, or in clinical trial phases. Fortunately, some novel antiviral strategies, such as convalescent plasma, clustered regularly interspaced short palindromic repeats (CRISPR), and mesenchymal stem cell (MSC) therapy, potentially offer an additional or alternative option or compassionate use for the people suffering from COVID-19, especially for critically ill patients, although their safety and efficacy are also under study. In this review, we explore the applications, possible mechanisms, and efficacy in successful cases using convalescent plasma, CRISPR, and MSC therapy for COVID-19 treatment, respectively. Furthermore, the perspectives and limitations of these novel antiviral strategies are evaluated.<\/jats:p>","DOI":"10.3390\/microorganisms8091259","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T09:35:31Z","timestamp":1597916131000},"page":"1259","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel Antiviral Strategies in the Treatment of COVID-19: A Review"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-527X","authenticated-orcid":false,"given":"Shiu-Jau","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Mackay Memorial Hospital, Taipei 10449, Taiwan"},{"name":"Department of Medicine, Mackay Medical College, New Taipei City 25245, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-5338","authenticated-orcid":false,"given":"Shao-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Jianan Psychiatric Center, Ministry of Health and Welfare, Tainan 71742, Taiwan"},{"name":"Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-2845","authenticated-orcid":false,"given":"Yuan-Chuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Gloria Operation Center, National Tsing Hua University, Hsinchu City 30013, Taiwan"},{"name":"Program in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","article-title":"Hosts and sources of endemic human coronaviruses","volume":"Volume 100","author":"Corman","year":"2018","journal-title":"Advances in Virus Research"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis Version 2","volume":"Volume 1282","author":"Fehr","year":"2015","journal-title":"Coronaviruses"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/risa.13500","article-title":"Consideration of the aerosol transmission for COVID-19 and public health","volume":"40","author":"Anderson","year":"2020","journal-title":"Risk Anal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2000352","DOI":"10.1183\/13993003.00352-2020","article-title":"More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: Experience from China","volume":"55","author":"Guan","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Setti, L., Passarini, F., De Gennaro, G., Barbieri, P., Perrone, M.G., Borelli, M., Palmisani, J., Di Gilio, A., Piscitelli, P., and Miani, A. (2020). Airborne transmission route of COVID-19: Why 2 meters\/6 feet of inter-personal distance could not be enough. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17082932"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40246-020-00267-3","article-title":"COVID-19 vulnerability: The potential impact of genetic susceptibility and airborne transmission","volume":"14","author":"Peccia","year":"2020","journal-title":"Hum. Genom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1053\/j.gastro.2020.02.054","article-title":"COVID-19: Gastrointestinal manifestations and potential fecal\u2014Oral transmission","volume":"158","author":"Gu","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/jmv.25825","article-title":"The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/apt.15731","article-title":"Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission","volume":"51","author":"Tian","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"m1165","DOI":"10.1136\/bmj.m1165","article-title":"Covid-19: Identifying and isolating asymptomatic people helped eliminate virus in Italian village","volume":"368","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11427-020-1661-4","article-title":"Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China","volume":"63","author":"Hu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Syal, K. (2020). COVID-19 herd immunity and convalescent plasma transfer therapy. J. Med. Virol.","DOI":"10.1002\/jmv.25870"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/1817-1737.185760","article-title":"High-flow nasal oxygen versus noninvasive ventilation for hypoxemic respiratory failure: Do we know enough?","volume":"11","author":"Spoletini","year":"2016","journal-title":"Ann. Thorac. Med."},{"key":"ref_21","unstructured":"Shapiro, B.A. (1991). Clinical Application of Respiratory Care, Mosby."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0140-6736(09)60496-7","article-title":"Non-invasive ventilation in acute respiratory failure","volume":"374","author":"Nava","year":"2009","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000341754","article-title":"High-flow nasal cannulae for respiratory support of preterm infants: A review of the evidence","volume":"102","author":"Manley","year":"2012","journal-title":"Neonatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(09)61069-2","article-title":"Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial","volume":"374","author":"Peek","year":"2009","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1164\/rccm.202003-0817LE","article-title":"Covid-19 does not lead to a \u201ctypical\u201d acute respiratory distress syndrome","volume":"201","author":"Gattinoni","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00134-007-0933-3","article-title":"Steroid treatment in ARDS: A critical appraisal of the ARDS network trial and the recent literature","volume":"34","author":"Meduri","year":"2008","journal-title":"Intensive Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1378\/chest.06-2100","article-title":"Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial","volume":"131","author":"Meduri","year":"2007","journal-title":"Chest"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses\u2014Drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.tmaid.2020.101615","article-title":"Remdesivir as a possible therapeutic option for the COVID-19","volume":"34","author":"Memish","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., Hohmann, E., Chu, H.Y., Luetkemeyer, A., and Kline, S. (2020). ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19\u2014Preliminary Report. N. Engl. J. Med., Online ahead of print.","DOI":"10.1056\/NEJMoa2007764"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_34","first-page":"4539","article-title":"Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19","volume":"24","author":"Meo","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gautret, P., Lagier, J.-C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., and Dupont, H.T. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 105949.","DOI":"10.1101\/2020.03.16.20037135"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\u2014Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., and Yang, Y. (2020). Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering.","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir\u2014A potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J. Virus Erad."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"78","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S., Boffini, N., Da Prat, V., Di Terlizzi, G., and Lanzillotta, M. (2020). Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann. Rheum. Dis., 1\u20139.","DOI":"10.1136\/annrheumdis-2020-218122"},{"key":"ref_47","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud Publica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2020-0035","article-title":"COVID-19 pandemic: An overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeutics","volume":"11","author":"Amawi","year":"2020","journal-title":"Ther. Deliv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108517","DOI":"10.1016\/j.clim.2020.108517","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.18632\/aging.103102","article-title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., and Lv, T. (2020). Treatment with convalescent plasma for COVID-19 patients in Wuhan.; China. J. Med. Virol., 1\u201312.","DOI":"10.1002\/jmv.25882"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_58","first-page":"865","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"81","author":"Bloch","year":"2020","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Rajendran, K., Krishnasamy, N., Rangarajan, J., Rathinam, J., Natarajan, M., and Ramachandran, A. (2020). Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. Med. Virol., 1.","DOI":"10.1002\/jmv.25961"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, Y.C., Sheng, J., Trang, P., and Liu, F. (2018). Potential application of the CRISPR\/Cas9 system against herpesvirus infections. Viruses, 10.","DOI":"10.3390\/v10060291"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, Y.C. (2019). Introductory chapter: Gene editing technologies and Applications. Gene Editing-Technologies and Applications, IntechOpen.","DOI":"10.5772\/intechopen.85499"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wang, S.C., Chen, Y.C., Lee, C.H., and Cheng, C.M. (2019). Opioid addiction, genetic susceptibility and medical treatments: A Review. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174294"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza","volume":"81","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","article-title":"Mesenchymal stem cell therapy for COVID-19: Present or future","volume":"16","author":"Golchin","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2000858","DOI":"10.1183\/13993003.00858-2020","article-title":"Current status of cell-based therapies for respiratory virus infections: Applicability to COVID-19","volume":"55","author":"Khoury","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2\u2014Mesenchymal stem cells improve the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis."},{"key":"ref_67","first-page":"E71","article-title":"Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: The case for compassionate use","volume":"23","author":"Atluri","year":"2020","journal-title":"Pain Physician"},{"key":"ref_68","unstructured":"(2020, April 20). US FDA Website, Available online: https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-access."},{"key":"ref_69","unstructured":"(2020, April 02). EMA Website. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/compassionate-use."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2019.04.008","article-title":"Convalescent plasma therapy for persistent hepatitis E virus infection","volume":"71","author":"Ankcorn","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_71","first-page":"152","article-title":"Convalescent plasma new evidence for an old therapeutic tool","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.transci.2016.12.014","article-title":"Use of convalescent plasma in Ebola virus infection","volume":"56","author":"Garraud","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tiberghien, P., de Lamballerie, X., Morel, P., Gallian, P., Lacombe, K., and Yazdanpanah, Y. (2020). Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how?. Vox Sang.","DOI":"10.1111\/vox.12926"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Roback, J.D., and Guarner, J. (2020). Convalescent plasma to treat COVID-19 possibilities, challenges. JAMA.","DOI":"10.1001\/jama.2020.4940"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","article-title":"CRISPR-Cas9 for cancer therapy: Opportunities and challenges","volume":"447","author":"Chen","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.omtn.2019.02.027","article-title":"Genome-editing technologies: Concept, pros, and cons of various genome\u2014Editing techniques and bioethical concerns for clinical application","volume":"16","author":"Khan","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"BSR20200127","DOI":"10.1042\/BSR20200127","article-title":"Gene editing and CRISPR in the clinic: Current and future perspectives","volume":"40","author":"Hirakawa","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/17425247.2018.1517746","article-title":"Delivery approaches for CRISPR\/Cas9 therapeutics in vivo: Advances and challenges","volume":"15","author":"Luther","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: A review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bari, E., Ferrarotti, I., Saracino, L., Perteghella, S., Torre, M.L., and Corsico, A.G. (2020). Mesenchymal stromal cell secretome for severe COVID-19 infections: Premises for the therapeutic use. Cells, 9.","DOI":"10.3390\/cells9040924"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/9\/1259\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:03:47Z","timestamp":1760177027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/9\/1259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":84,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["microorganisms8091259"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms8091259","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}